Endonovo Therapeutics 

$0.000100
8
+$0.00+100%Friday 17:32

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.0002
52W Low
0.00005
Volume
500,000
Avg. Volume
341,782
Mkt Cap
180,755.6
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

Nov 21Expected
Q3 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
-0.07
0
0.08
0.15
Expected EPS
N/A
Actual EPS
-0.0039

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-2.18MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Baxter International
BAX
Mkt Cap12.14B
Baxter International Inc. offers medical devices and therapies that compete with Endonovo's therapeutic solutions.
Medtronic
MDT
Mkt Cap110.49B
Medtronic plc provides medical technologies, services, and solutions, including those for pain management and restorative therapies, competing with Endonovo's offerings.
Boston Scientific
BSX
Mkt Cap61.74B
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties, overlapping with Endonovo's market.
Abbott Laboratories
ABT
Mkt Cap168.71B
Abbott Laboratories operates in the healthcare sector providing a broad range of medical devices, competing in areas similar to Endonovo.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of products in the healthcare field, including medical devices that compete with Endonovo.
Smith & Nephew
SNN
Mkt Cap11.06B
Smith & Nephew plc designs, manufactures, and markets medical devices for the orthopedic market, competing with Endonovo's therapeutic technologies.
Stryker
SYK
Mkt Cap105.65B
Stryker Corporation specializes in medical technologies, including surgical equipment and neurovascular products, which can be seen as competitive to Endonovo's solutions.
Zimmer Biomet
ZBH
Mkt Cap16.84B
Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products; competing in the medical device sector against Endonovo.
Edwards Lifesciences
EW
Mkt Cap49.08B
Edwards Lifesciences Corporation specializes in heart valves and hemodynamic monitoring, competing in the broader medical device market against Endonovo.

About

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
Show More
CEO
Alan Brian Collier
Employees
1
Country
United States
ISIN
US29272H3003

Listings

0 Comments

Share your thoughts

FAQs

What is Endonovo Therapeutics stock price today?▼
The current price of ENDV is $0.00 USD — it has increased by +100% in the past 24 hours. Watch Endonovo Therapeutics stock price performance more closely on the chart.
What is Endonovo Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Endonovo Therapeutics stocks are traded under the ticker ENDV.
Is Endonovo Therapeutics stock price growing?▼
ENDV stock has risen by +0% compared to the previous week, the month change is a +100% rise, over the last year Endonovo Therapeutics has showed a -50% decrease.
What is Endonovo Therapeutics market cap?▼
Today Endonovo Therapeutics has the market capitalization of 180,755.6
What were Endonovo Therapeutics earnings last quarter?▼
ENDV earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Endonovo Therapeutics revenue for the last year?▼
Endonovo Therapeutics revenue for the last year amounts to 0 USD.
What is Endonovo Therapeutics net income for the last year?▼
ENDV net income for the last year is -2.18M USD.
How many employees does Endonovo Therapeutics have?▼
As of November 1, 2026, the company has 1 employees.
In which sector is Endonovo Therapeutics located?▼
Endonovo Therapeutics operates in the Health & Wellness sector.
When did Endonovo Therapeutics complete a stock split?▼
The last stock split for Endonovo Therapeutics was on December 20, 2019 with a ratio of 1:1000.
Where is Endonovo Therapeutics headquartered?▼
Endonovo Therapeutics is headquartered in Woodland Hills, United States.